REALISE demonstrated that patients with baseline anemia experienced improvements in spleen size and MF-related symptoms with ruxolitinib treatment, and median Hb levels remained stable throughout the study, with red blood cell (RBC) transfusion requirements decreasing or remaining stable [12]. Here, GSTM1 is linked to anemia (phenotype).